But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. There are plenty of strategies for discovering value stocks, but we have found that ...

Study data reveal how a specific sequence of cancer therapies can improve outcomes for patients with hard-to-treat lymphomasRelapsed/refractory (R/R ...

Study data reveal how a specific sequence of cancer therapies can improve outcomes for patients with hard-to-treat lymphomas ...

Neoadjuvant PD-1 blockade in early-stage mismatch repair–deficient solid rectal and non-rectal tumors can eliminate the need ...

A combination of pertuzimab and Enhertu can slow disease progression and improve survival in people with HER2-positive ...

Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with ...

AstraZeneca reports mixed first-quarter 2025 results. The fall in pre-market is likely due to the soft sales performance of ...

New data presented at AACR supports adding pembrolizumab before and after surgery in patients with newly diagnosed locally ...

The famous trees, and the festival associated with their blossoming each spring, is part of a tradition for the global ...

The US FDA has granted breakthrough device designation to Roche's companion diagnostic VENTANA TROP2 (EPR20043) RxDx Device.

RxDx Device is an immunohistochemistry (IHC) assay combined with a digital pathology algorithm to determine patient treatment. The device uses artificial intelligence-based ...

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...